Cellavision Q4’24: A bit more uncertain outlook - Redeye
Bildkälla: Stockfoto

Cellavision Q4’24: A bit more uncertain outlook - Redeye

Redeye’s view on the Q4 report. The organic growth was weak, with large swings in the development in the different regions. Gross margin held up well. We have decreased our sales estimates further due to the volatility in the geographical areas. With these changes we lower our Base case SEK 228 (250) and the fair value range of SEK 160 – 348 per share. Following this report, we change the lead analyst for the company.

Redeye’s view on the Q4 report. The organic growth was weak, with large swings in the development in the different regions. Gross margin held up well. We have decreased our sales estimates further due to the volatility in the geographical areas. With these changes we lower our Base case SEK 228 (250) and the fair value range of SEK 160 – 348 per share. Following this report, we change the lead analyst for the company.
Börsvärldens nyhetsbrev
ANNONSER